Allergan's Bid To Block Imprimis Drug Sales Limited To Calif.

Law360 (July 11, 2019, 11:09 PM EDT) -- A California federal court on Thursday handed a partial win to Allergan USA Inc. by blocking the compound drugmaker Imprimis Pharmaceuticals from selling medications under certain conditions, though the judge limited the order's scope to the Golden State.

U.S. District Judge David O. Carter ruled that San Diego-headquartered Imprimis should be barred from selling any drug in California unless the company can prove that the drug is destined for a specific patient who has a prescription for it.

Allergan asked in May for a nationwide injunction to that effect, days after a jury awarded the company $48,500, finding Imprimis cost Allergan...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related

Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

California Central

Nature of Suit

Other Statutory Actions

Judge

Subscribers Only

Date Filed

September 7, 2017

Law Firms

Companies

Government Agencies

Judge Analytics